Diffusion-weighted MRI in early assessment of tumour response to radiotherapy in high-risk prostate cancer

British Journal of Radiology

Volumn 87, Issue 1043, 2014, Pages

  Liu, L ^a   Wu, N ^a   Ouyang, H ^a   Dai, J R ^a   Wang, W H ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MIDDLE AGED; PROCEDURES; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIFFUSION MAGNETIC RESONANCE IMAGING; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; ROC CURVE; TIME FACTORS;

EID: 84908668925     PISSN: 00071285     EISSN: 1748880X     Source Type: Journal    
DOI: 10.1259/bjr.20140359     Document Type: Article

References (29)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics. CA Cancer J Clin 2005; 55: 10-30. doi: 10.3322/caac.20073
2. Zhang L, Wu S, Guo LR, Zhao XJ. Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China. Asian J Androl 2009; 11: 9-13. doi: 10.1038/aja.2008.21
3. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008; 9: 445-52. doi: 10.1016/S1470-2045(08)70104-9
4. Dudeck O, Zeile M, Wybranski C, Schulmeister A, Fischbach F, Pech M, et al. Early prediction of anticancer effects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy. Eur Radiol 2010; 20: 2699-706. doi: 10.1007/s00330-010-1846-z
5. Wybranski C, Zeile M, Löwenthal D, Fischbach F, Pech M, Röhl FW, et al. Value of diffusion weighted MR imaging as an early surrogate parameter for evaluation of tumor response to high-dose-rate brachytherapy of colorectal liver metastases. Radiat Oncol 2011; 6: 43. doi: 10.1186/1748-717X-6-43
6. Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006; 24: 843-7.
7. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007; 25: 4104-9.
8. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8: 162-200.
9. Marciscano AE, Hardee ME, Sanfilippo N. Management of high-risk localized prostate cancer. Adv Urol 2012; 2012: 641689. doi: 10.1155/2012/641689
10. Bastian PJ, Boorjian SA, Bossi A, Briganti A, Heidenreich A, Freedland SJ, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol 2012; 61: 1096-106. doi:10.1016/j.eururo.2012.02.031
11. Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with doseescalated radiation therapy across multiple definitions of high-risk disease. Int J Radiat Oncol Phys 2011; 81: e335-44. doi: 10.1016/j.ijrobp.2011.04.037
12. Brawer MK. Radiation therapy failure in prostate cancer patients: risk factors and methods of detection. Rev Urol 2002; 4: S2-11.
13. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOGASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-74.
14. Padhani AR. Functional MRI for anticancer therapy assessment. Eur J Cancer 2002; 38: 2116-27.
15. Hein P, Kremser C, Judmaier W, Griebel J, Pfeiffer KP, Kreczy A, et al. Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol 2003; 45: 214-22.
16. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007; 188: 1622-35.
17. Theilmann RJ, Borders R, Trouard TP, Xia G, Outwater E, Ranger-Moore J, et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 2004; 6: 831-7.
18. Eccles CL, Haider EA, Haider MA, Fung S, Lockwood G, Dawson LA. Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations. Acta Oncol 2009; 48: 1034-43. doi: 10.1080/02841860903099972
19. Herneth AM, Guccione S, Bednarski M. Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. Eur J Radiol 2003; 45: 208-13.
20. Afaq A, Andreou A, Koh DM. Diffusion weighted magnetic resonance imaging for tumor response assessment: why, when and how? Cancer Imaging 2010; 10 Spec no A: S179-88. doi: 10.1102/1470-7330.2010.9032
21. Zhao M, Pipe JG, Bonnett J, Evelhoch JL. Early detection of treatment response by diffusion weighted 1H-NMR spectroscopy in a murine tumor in vivo. Br J Cancer 1996; 73: 61-4.
22. Kim CK, Park BK, Lee HM. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging 2009; 29: 391-7. doi: 10.1002/jmri.21645
23. Harry VN, Semple SI, Gilbert FJ, Parkin DE. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008; 111: 213-20. doi: 10.1016/j.ygyno.2008.07.048
24. Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion weighted MRI. Clin Cancer Res 2012; 18: 1146-55. doi: 10.1158/1078-0432.CCR-11-0625.
25. Song I, Kim CK, Park BK, Park W. Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. AJR Am J Roentgenol 2010; 194: W477-82. doi: 10.2214/AJR.09.3557
26. Roznovanu SL, Rədulescu D, Novac C, Stolnicu S. The morphologic changes induced by hormone and radiation therapy on prostate carcinoma. Rev Med Chir Soc Med Nat Iasi 2005; 109: 337-42.
27. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299: 289-95. doi: 10.1001/jama.299.3.289
28. Barrett T, Gill AB, Kataoka MY, Priest AN, Joubert I, McLean MA, et al. DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study. Magn Reson Med 2012; 67: 778-85. doi: 10.1002/mrm.23062
29. Petraki CD, Sfikas CP. Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol 2007; 22: 107-18.